| Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635) |
|---|
| 10/18/2001 | US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide |
| 10/18/2001 | US20010031747 Progestin therapy for maintaining amenorrhea |
| 10/18/2001 | US20010031731 Free radical scavengers or promoters thereof as therapeutic adjuvants in preterm parturition |
| 10/18/2001 | DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma |
| 10/18/2001 | DE10013782A1 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln 4-fluoroalkyl-2H-benzopyrans with antiestrogenic action, processes for their preparation, pharmaceutical compositions containing them and their use for the preparation of medicaments |
| 10/18/2001 | CA2406485A1 Hpv-specific short-mers |
| 10/18/2001 | CA2406033A1 Anti-d monoclonal antibodies |
| 10/18/2001 | CA2405912A1 Albumin fusion proteins |
| 10/18/2001 | CA2405793A1 Combination of organic compounds |
| 10/18/2001 | CA2405476A1 Compounds and methods for modulating endothelial cell adhesion |
| 10/18/2001 | CA2405419A1 Apomorphine derivatives and methods for their use |
| 10/18/2001 | CA2405070A1 Estrogen agonist/antagonist metabolites |
| 10/18/2001 | CA2404988A1 Listeria monocytogenes genome, polypeptides and uses |
| 10/18/2001 | CA2404971A1 Human protein kinases and protein kinase-like enzymes |
| 10/18/2001 | CA2404634A1 Human mullerian duct-derived epithelial cells and methods of isolation and uses thereof |
| 10/18/2001 | CA2403365A1 Quinazoline compounds |
| 10/18/2001 | CA2402410A1 The high bone mass gene of 11q13.3 |
| 10/17/2001 | EP1144997A2 Methods and compounds for modulating nuclear receptor activity |
| 10/17/2001 | EP1144648A1 Cyclic nucleotide-associated proteins |
| 10/17/2001 | EP1144627A2 Proteins capable of triggering g2/m transition and of interacting with cdc2- and cyclin b |
| 10/17/2001 | EP1144625A2 Nucleic-acid binding proteins |
| 10/17/2001 | EP1144614A2 33 human secreted proteins |
| 10/17/2001 | EP1144598A2 Human homologues of proteins regulated by circadian rhythms |
| 10/17/2001 | EP1144451A2 Method of modulating cell differentiation or neoplastic trnasformation by altering cadherin-11 expression or function |
| 10/17/2001 | EP1144443A2 Human membrane transport proteins |
| 10/17/2001 | EP1144410A2 Use of imidazo 1,5-a]-pyrido 3,2-e]-pyrazinones as medicaments |
| 10/17/2001 | EP1144409A2 Phenyl urea and phenyl thiourea derivatives |
| 10/17/2001 | EP1144405A1 Triazole compounds with dopamine-d3-receptor affinity |
| 10/17/2001 | EP1144396A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 10/17/2001 | EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 10/17/2001 | EP1144003A1 Methods and devices for delivery of agents to breast milk ducts |
| 10/17/2001 | EP1143997A1 Tumor necrosis factor antagonists and their use in endometriosis |
| 10/17/2001 | EP1143987A1 Natural composition and method for the treatment of sexual dysfunction |
| 10/17/2001 | EP1143978A2 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
| 10/17/2001 | EP1143964A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission |
| 10/17/2001 | EP1143961A2 Regulators of the ptc or smoothened pathway, compositions and uses related thereto |
| 10/17/2001 | EP1143955A2 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| 10/17/2001 | EP1143946A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 10/17/2001 | EP1143940A2 Compositions and methods for mucosal delivery |
| 10/17/2001 | EP1143932A1 Transnasal transport/immunisation with highly adaptable carriers |
| 10/17/2001 | EP1039894B1 Compositions for increasing the concentration and/or motility of spermatozoa in humans |
| 10/17/2001 | EP0942911B1 Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds |
| 10/17/2001 | EP0796251B1 Uracil derivatives |
| 10/17/2001 | CN1318059A Isoquinolines as urokinase inhibitors |
| 10/17/2001 | CN1318053A Cyclopentanoue dihydropyridine compounds useful as potassium channel openers |
| 10/17/2001 | CN1317966A Utilization of aryl (or heteroaryl) azolylcarbinol derivatives in prepn. of medicament for treating troubles mediated by excess of substance P |
| 10/17/2001 | CN1317338A Disinfectant for treating superficial vulve fungus infection and its preparing process |
| 10/17/2001 | CN1072935C Prepn. method for medical compsns. contg. aza-steroid compound for treating prostatic hyperplasia |
| 10/17/2001 | CN1072932C Method of preventing emesis and treating sexual dyfunction using tetra hydrobenz [CD] indole-6-carboxamides |
| 10/16/2001 | US6303789 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| 10/16/2001 | US6303627 For therapy of physiological and psychological disorders |
| 10/16/2001 | US6303606 Use of selective antagonists of the α1B-adrenergic receptor for improvement of sexual dysfunction |
| 10/16/2001 | US6303601 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 10/16/2001 | US6303126 Treatment of fibrosis by HGF |
| 10/16/2001 | US6303123 Which bind and neutralize the hormone gnrh in vivo. |
| 10/11/2001 | WO2001075108A1 Human ion channel protein and polynucleotides encoding the same |
| 10/11/2001 | WO2001074903A2 CD20/IgE-RECEPTOR LIKE MOLECULES AND USES THEREOF |
| 10/11/2001 | WO2001074896A1 Human polynucleotides, polypeptides, and antibodies |
| 10/11/2001 | WO2001074840A2 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 10/11/2001 | WO2001074839A2 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use |
| 10/11/2001 | WO2001074775A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 10/11/2001 | WO2001074769A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 10/11/2001 | WO2001074369A1 Divided dose therapies with vascular damaging activity |
| 10/11/2001 | WO2001074359A1 Sigma receptor ligands and their medical uses |
| 10/11/2001 | WO2001074358A1 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels |
| 10/11/2001 | WO2001036640A3 Human fgf-21 gene and gene expression products |
| 10/11/2001 | WO2001032702A9 Molecular structure of rhd negative locus |
| 10/11/2001 | WO2001025269A3 Human g-protein coupled receptor |
| 10/11/2001 | WO2001025210A3 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands |
| 10/11/2001 | US20010029357 Enhanced intra vaginal devices |
| 10/11/2001 | US20010029304 Cyclopentane heptan (ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 10/11/2001 | CA2404896A1 Human ion channel protein and polynucleotides encoding the same |
| 10/11/2001 | CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 10/11/2001 | CA2404074A1 Human polynucleotides, polypeptides, and antibodies |
| 10/11/2001 | CA2403791A1 Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels |
| 10/11/2001 | CA2402078A1 Divided dose therapies with vascular damaging activity |
| 10/11/2001 | CA2401948A1 Cd20/ige-receptor like molecules and uses thereof |
| 10/11/2001 | CA2401137A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 10/10/2001 | EP1143000A1 Screening method |
| 10/10/2001 | EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents |
| 10/10/2001 | EP1142880A1 Benzimidazole derivatives |
| 10/10/2001 | EP1142580A1 Use of peptide |
| 10/10/2001 | EP1141339A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| 10/10/2001 | EP1141296A2 Interferon-epsilon |
| 10/10/2001 | EP1141287A1 Pancreatic polypeptide zsig66 |
| 10/10/2001 | EP1141020A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 10/10/2001 | EP1141018A2 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 10/10/2001 | EP1141015A1 Insulin-like growth factor (igf) i mutant variants |
| 10/10/2001 | EP1140946A2 Quinoline derivatives |
| 10/10/2001 | EP1140945A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 10/10/2001 | EP1140934A1 BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS |
| 10/10/2001 | EP1140931A1 5ht1 antagonists for antidepressant therapy |
| 10/10/2001 | EP1140914A1 Non-peptide nk1 receptors antagonists |
| 10/10/2001 | EP1140912A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 10/10/2001 | EP1140911A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
| 10/10/2001 | EP1140908A1 Triazole compounds with dopamine-d3-receptor affinity |
| 10/10/2001 | EP1140907A1 Triazole compounds with dopamine-d3-receptor affinity |
| 10/10/2001 | EP1140906A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders |
| 10/10/2001 | EP1140900A2 Pyrazole compounds and uses thereof |
| 10/10/2001 | EP1140898A1 Amide and urea derivatives as 5-ht reuptake inhibitors and as 5-ht1b/1d ligands |